CN Patent

CN102083413A — 用于治疗高眼压和青光眼的方法和组合物

Assigned to Santen Pharmaceutical Co Ltd · Expires 2011-06-01 · 15y expired

What this patent protects

本发明涉及含有PGF2α类似物用于治疗高眼压和青光眼的眼用含水组合物，通过给予需要这种治疗的受试者所述的组合物治疗高眼压和青光眼的方法，以及增加含水组合物中PGF2α类似物的水溶性和稳定性的方法。

USPTO Abstract

本发明涉及含有PGF2α类似物用于治疗高眼压和青光眼的眼用含水组合物，通过给予需要这种治疗的受试者所述的组合物治疗高眼压和青光眼的方法，以及增加含水组合物中PGF2α类似物的水溶性和稳定性的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN102083413A
Jurisdiction: CN
Classification: —
Expires: 2011-06-01
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.